APLT

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-19.3K ExitQ1 2026 $19k -- $0.103
Paul Tudor Jones IITudor Investment $-5.7K ExitQ1 2026 $5.7k -- $0.103
Steven CohenPoint72 $-1.7K ExitQ1 2026 $1.7k -- $0.103
Jim SimonsRenaissance Technologies $-270.6K ExitQ1 2026 $271k -- $0.103
Ken GriffinCitadel Advisors $-133.2K TrimQ4 2025 $133k -- $0.103
Paul Tudor Jones IITudor Investment $-17.9K ExitQ3 2025 $18k -- $0.103

Insider Trades

Name	Value	Action	Price	Current Price
Kanter Stacy J.Director $4.8k43k shares SellDec 16, 2025 $0.112 $0.103
Perfetti RiccardoChief Medical Officer $4.6k10.4k shares SellMar 4, 2025 $0.44 $0.103
Chinoporos ConstantineSee Remarks $197447 shares SellMar 4, 2025 $0.44 $0.103
Funtleyder Leslie D.Director, Officer: See Remarks $6.4k14.5k shares SellMar 4, 2025 $0.44 $0.103
Perfetti RiccardoChief Medical Officer $53k86.1k shares SellFeb 6, 2025 $0.61 $0.103
Chinoporos ConstantineSee Remarks $17k28.1k shares SellFeb 6, 2025 $0.61 $0.103

Trade APLT

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. Another key compound, AT-001, is currently undergoing pivotal Phase III clinical trials. This therapy is being evaluated for its efficacy in treating both diabetic cardiomyopathy and diabetic peripheral neuropathy. Beyond its clinical pipeline, the company also maintains an early-stage preclinical portfolio. This includes AT-003, which is being developed for diabetic retinopathy, and AT-104. AT-104 is a PI3K inhibitor specifically designed to target T-Cell Acute Lymphoblastic Leukemia, a rare form of blood cancer. Applied Therapeutics, Inc. was established in 2016 and operates from its headquarters in New York City.

CEO: Les D. Funtleyder
IPO Date: May 14, 2019

Market Data

Open: $0.103
High: $0.103
Low: $0.103
Volume: 2.7M
Avg Volume: 15.8M
52W High: $1.50
52W Low: $0.09

Valuation

Market Cap: $14.9M
Enterprise Value: $5.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$84.3M
Revenue: $455K
Net Income: -$105.6M
Cash: $79.4M
Debt: $2.8M

Events

EarningsNov 13

EPS est. -0.14097 · actual -0.13046